Teeraya Puavilai

Teeraya Puavilai

Auto-generated profile, based on publicly available information

Teeraya Puavilai

Division of Hematology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2019 in Leukemia Research
Verified
Journal Article
Closed access
WLWasithep Limvorapitak
Wasithep Limvorapitak
WOWeerapat Owattanapanich
Weerapat Owattanapanich
EUEakkapol Utchariyaprasit
Eakkapol Utchariyaprasit
PNpimjai niparuck
pimjai niparuck
TPTeeraya Puavilai
Teeraya Puavilai
KPKannadit Prayongratana
Kannadit Prayongratana

1 August 2023 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
CKChaninan Kositkuljorn
Chaninan Kositkuljorn
SRSuthinee Rutnin
Suthinee Rutnin
TRTeerapong Rattananukrom
Teerapong Rattananukrom
TPTeeraya Puavilai
Teeraya Puavilai
BKBurana Khiankaew
Burana Khiankaew
WIWimolsiri Iamsumang
Wimolsiri Iamsumang
Methotrexate-related lymphoproliferative disorders (MTX-LPDs) are immunodeficiency diseases following methotrexate (MTX) administration, mainly occurring in rheumatoid arthritis patients. Although uncommon, MTX-LPDs have been reported in some patients with psoriasis, dermatomyositis, and cutaneous T-cell lymphoma (CTCL) who received MTX. Granulomatous mycosis fungoides (GMF) is a rare subtype of cutaneous T-cell lymphoma, where MTX is one of the treatment options in recalcitrant cases. Herein, we report a case of a 72-year-old female patient with GMF who additionally developed cutaneous Epstein–Barr virus (EBV)-positive diffuse large B-cell lymphoma (DLBCL) during MTX treatment. According to the 5th edition of the WHO classification of Haematolymphoid Tumors (WHO-HAEM), this condition is currently categorized as “lymphoma arising in immunodeficiency/dysregulation”. In this article, we also reviewed published literature on cutaneous MTX-LPDs in the setting of CTCL. This entity should be considered in cases of new, atypical skin nodules and/or plaques in CTCL patients receiving long-term MTX treatment.

24 May 2023 in European Journal of Haematology
Verified
Journal Article
Open access
SPSomsak Prasongtanakij
Somsak Prasongtanakij
SPSarinthip Preedagasamzin
Sarinthip Preedagasamzin
BJBunyada Jittorntrum
Bunyada Jittorntrum
UAUsanarat Anurathapan
Usanarat Anurathapan
TPTeeraya Puavilai
Teeraya Puavilai
SHSuradej Hongeng
Suradej Hongeng
Objectives: Multiple myeloma (MM) accounts for 10% of hematologic malignancies. However, most of the patients suffered from relapsed/refractory disease. We would like to expand CAR T cell therapy to treat MM using our current platform.Methods: BCMA CAR T lymphocytes were generated for volunteers or MM patients. The transduction efficiency was detected by the ddPCR technique. Immunophenotyping and exhaustion markers were monitored by flow cytometry. The efficacy of BCMA CAR T cells was tested using coculturing with BCMA CAR or mock, and the positive and negative targets, K562/hBCMA‐ECTM and K562, respectively.Results: BCMA CAR T cells were generated from consented volunteers or MM patients and could be detected CAR BCMA expression at a mean of 4.07 ± 1.95 or 4.65 ± 1.21 copies/cell, respectively. Those modified T cells were primarily effector memory T cells. Our BCMA CAR T cells could explicitly eradicate the K562/hBCMA‐ECTM cell line while the K562 cell line survived. Interestingly, the BCMA CAR, mock T cells, and peripheral blood mononuclear cells from MM patients expressed similar levels of the exhaustion makers, TIM‐3, LAG‐3, and PD1.Conclusions: Our BCMA CAR T cells, mainly effector/effector memory, could eliminate BCMA‐expressing cells in vitro and had similar levels of exhaustion markers among different populations.